{'fraction_non_alphanumeric': 0.015767634854771784, 'fraction_numerical': 0.018257261410788383, 'mean_word_length': 5.483870967741935, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pulmonary embolism and covid-19

Aims There is increasing concern amongst clinicians of a possible increase in venous thromboembolism (VTE) events in patients with COVID-19 There remains limited data defining the incidence of VTE in this population and thus also a paucity of research examining the impact of targeted treatment in patients with thrombotic complications Methods We examined the number of symptomatic VTE events amongst proven COVID-19 patients admitted to a tertiary level academic hospital, over a one-month period Patient characteristics, admission and discharge inflammatory and coagulation markers were included in the analysis Results Sixty-one patients were identified Twelve patients (19 6%) admitted with COVID-19 were treated for a suspected PE Of these patients, 3 patients were discharged on anticoagulation, 3 died and 6 remain inpatients at the end of the study period Discussion COVID-19 patients are at increased risk of VTE This risk may extend beyond the period of admission Further research examining the role of extending the duration of thromboprophylaxis in COVID-19 patients beyond hospital discharge is warranted © 2020, Irish Medical Association All rights reserved